Cargando…
Development and validation of a hypoxia-related gene signature to predict overall survival in early-stage lung adenocarcinoma patients
BACKGROUND: Patients with early-stage lung adenocarcinoma (LUAD) exhibit significant heterogeneity in overall survival. The current tumour-node-metastasis staging system is insufficient to provide precise prediction for prognosis. METHODS: We quantified the levels of various hallmarks of cancer and...
Autores principales: | Sun, Jing, Zhao, Tianyu, Zhao, Di, Qi, Xin, Bao, Xuanwen, Shi, Run, Su, Chuan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7333486/ https://www.ncbi.nlm.nih.gov/pubmed/32655701 http://dx.doi.org/10.1177/1758835920937904 |
Ejemplares similares
-
Mast cell‐based molecular subtypes and signature associated with clinical outcome in early‐stage lung adenocarcinoma
por: Bao, Xuanwen, et al.
Publicado: (2020) -
Immune landscape and a novel immunotherapy-related gene signature associated with clinical outcome in early-stage lung adenocarcinoma
por: Bao, Xuanwen, et al.
Publicado: (2020) -
A novel 4-gene signature for overall survival prediction in lung adenocarcinoma patients with lymph node metastasis
por: Wang, Yanfang, et al.
Publicado: (2019) -
Identification and validation of hypoxia-derived gene signatures to predict clinical outcomes and therapeutic responses in stage I lung adenocarcinoma patients
por: Shi, Run, et al.
Publicado: (2021) -
Identification and validation of a hypoxia-immune signature for overall survival prediction in lung adenocarcinoma
por: Li, Yong, et al.
Publicado: (2022)